1 Min Read
May 18 (Reuters) - Obseva SA
* Says intends to advance obe022 into a Phase 2A proof-of-concept clinical trial in second half of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.